Opioid Use Disorder: Endpoints For Demonstrating Effectiveness Of Drugs For Medication Assisted Treatment Guidance For Industry

The guidance was released on August 6, 2018, by the U.S. Food and Drug Administration (FDA). The guidance presents new scientific recommendations to encourage medication-assisted treatment (MAT) drug development for the treatment of opioid use disorder (OUD). The recommendations promote both creation and improvement of these drugs by offering new methods of measuring, as well as demonstrating the effectiveness and benefits of new or existing MAT . . .